CAR-T Cell Therapy

CAR-T Cell Therapy for Mesothelioma

Overview

Chimeric antigen receptor T-cell (CAR-T) therapy is an advanced form of immunotherapy in which a patient's own T cells are genetically engineered to recognize and destroy cancer cells. While CAR-T therapy has transformed the treatment of blood cancers — with six FDA-approved products achieving complete response rates as high as 90% in B-cell acute lymphoblastic leukemia — its application in solid tumors like malignant mesothelioma remains in early clinical stages. The landmark phase I trial at Memorial Sloan Kettering Cancer Center (MSKCC) demonstrated a 72% overall response rate using intrapleurally delivered mesothelin-targeted CAR-T cells combined with pembrolizumab, representing the most promising CAR-T result in any solid tumor to date. As of January 2026, five CAR-T clinical trials are actively recruiting mesothelioma patients, and 93 mesothelioma clinical trials are open worldwide.

CAR-T Cell Therapy
Therapy Type	Adoptive cell immunotherapy
Primary Target	Mesothelin (MSLN)
Target Expression	~66% of epithelioid mesotheliomas
Best ORR Achieved	72% (with pembrolizumab)
Key Delivery Route	Intrapleural (regional)
Pivotal Trial	MSKCC Phase I (NCT02414269)
12-Month OS	80.2% (with lymphodepletion)
FDA-Approved for Meso	Not yet (Phase I/II only)
Recruiting Trials	5+ (as of January 2026)
Manufacturing Time	3-5 weeks (vein-to-vein)
Estimated Cost	$373,000-$475,000 per infusion
Key Investigator	Dr. Prasad Adusumilli (MSKCC)

Key Facts

Key Facts About CAR-T Cell Therapy for Mesothelioma

CAR-T cells are a patient's own T cells genetically modified to express a chimeric antigen receptor that recognizes and kills cancer cells without requiring MHC presentation Mesothelin is the primary CAR-T target for mesothelioma, expressed in approximately 66% of epithelioid mesotheliomas, 28% of non-epithelioid subtypes, and 0% of sarcomatoid tumors The MSKCC phase I trial achieved a 72% overall response rate with intrapleural mesothelin-targeted CAR-T cells combined with pembrolizumab in malignant pleural mesothelioma patients Intrapleural delivery of CAR-T cells directly into the chest cavity is a key innovation that achieves higher local concentrations and lower systemic toxicity compared to intravenous delivery Among patients receiving lymphodepleting chemotherapy before CAR-T infusion at MSKCC, 12-month overall survival reached 80.2% Six CAR-T products are FDA-approved for blood cancers (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti), but no CAR-T product is yet approved for any solid tumor including mesothelioma CAR-T manufacturing takes 3-5 weeks from blood collection to infusion, with next-generation rapid manufacturing platforms potentially reducing this to 24-48 hours Current FDA-approved CAR-T therapies cost $373,000 to $475,000 per infusion, with total treatment expenses potentially exceeding $1 million Cytokine release syndrome (CRS) is the most common serious side effect, but has been notably milder in mesothelioma trials using intrapleural delivery compared to blood cancer treatments As of January 2026, five CAR-T clinical trials are actively recruiting mesothelioma patients at major academic cancer centers including MSKCC, MD Anderson, and NCI Mesothelioma patients exposed to asbestos through occupational or environmental contact may be eligible for compensation to help cover the costs of emerging treatments like CAR-T therapy

What Is CAR-T Cell Therapy?

CAR-T (chimeric antigen receptor T-cell) therapy is a form of adoptive cell immunotherapy in which a patient's own immune cells are collected, genetically reprogrammed in a laboratory, and then infused back into the body to fight cancer. The treatment represents a fundamentally different approach from traditional chemotherapy or radiation — rather than using drugs to kill cancer cells, CAR-T harnesses the patient's own immune system as a targeted cancer-fighting weapon.

The chimeric antigen receptor (CAR) is a synthetic fusion protein engineered with four key components. The extracellular domain consists of a single-chain variable fragment (scFv) derived from an antibody, which recognizes a specific protein on the surface of cancer cells. A hinge region provides structural flexibility, while a transmembrane domain anchors the receptor in the T-cell membrane. The intracellular signaling domains activate the T cell when the receptor binds its target antigen, triggering the T cell to destroy the cancer cell.

A critical advantage of CAR-T cells over conventional immune responses is that they recognize surface antigens directly, without requiring antigen presentation through the major histocompatibility complex (MHC). This is particularly important in mesothelioma and other cancers where tumor cells can downregulate MHC molecules to evade immune detection. By bypassing this requirement, CAR-T cells can identify and attack cancer cells that have learned to hide from normal immune surveillance.

Upon encountering a cancer cell bearing the target antigen, CAR-T cells activate through multiple killing mechanisms: perforin and granzyme-dependent cytolysis (punching holes in the cancer cell membrane), Fas ligand and TNF-α-induced apoptosis (triggering programmed cell death), and cytokine release (recruiting additional immune cells to the tumor site). CAR-T cells are often described as a "living drug" because they can persist in the body for months or years, expand in response to antigen encounter, and provide ongoing tumor surveillance — a capability that distinguishes them from other cancer therapies.

How Have CAR-T Cells Evolved Through Different Generations?

CAR designs have progressed through four successive generations, each incorporating additional signaling components to enhance T-cell function and persistence. Understanding these generations helps explain why current clinical trials use specific CAR architectures and how next-generation designs may improve outcomes for mesothelioma patients.

Generation	Signaling Domains	Key Features	Clinical Status
First	CD3ζ only	Limited persistence and expansion; early trials showed minimal efficacy	Historical
Second	CD3ζ + CD28 or 4-1BB	Standard in current clinical use; CD28 provides rapid expansion while 4-1BB enhances persistence	Current standard for mesothelioma trials
Third	CD3ζ + CD28 + 4-1BB	Combines benefits of both co-stimulatory domains for potentially superior function	Under evaluation
Fourth (Armored)	Second-gen + cytokine modules	Secrete IL-7, IL-12, or IL-15 to counteract immunosuppressive tumor microenvironment	Preclinical/early clinical

Second-generation CARs are the most commonly used in mesothelioma clinical trials. The choice between CD28 and 4-1BB co-stimulation has important implications: CD28-based CARs drive strong initial T-cell activation and rapid expansion but may be prone to exhaustion, while 4-1BB-based CARs promote enhanced persistence, memory formation, and resistance to exhaustion. The MSKCC mesothelioma program uses a CD28-co-stimulated CAR, while the University of Pennsylvania program employs a 4-1BB design — reflecting two complementary strategies for optimizing anti-tumor activity.

Fourth-generation "armored" CARs represent the most advanced designs, incorporating cytokine-secreting modules that allow the engineered T cells to actively remodel the hostile tumor microenvironment. These armored CARs can secrete pro-inflammatory cytokines like IL-7, IL-12, or IL-15 directly at the tumor site, converting an immunosuppressive environment into one that supports anti-tumor immune activity.

What Are the Primary CAR-T Targets for Mesothelioma?

Mesothelin — The Dominant Target

Mesothelin (MSLN) is a 40-kDa cell-surface glycoprotein normally expressed at low levels on mesothelial cells lining the pleura, peritoneum, and pericardium. In mesothelioma, mesothelin is significantly overexpressed, making it the most studied CAR-T target for this disease. A large tissue microarray study found mesothelin positivity in 69% of malignant mesotheliomas overall, with expression varying significantly by histological subtype: approximately 66% of epithelioid mesotheliomas, 28% of non-epithelioid subtypes, and 0% of sarcomatoid tumors stain positive for mesothelin.

Among positive specimens, roughly 70% showed moderate-to-strong staining intensity, but only 37% of epithelioid tumors had diffuse expression in more than half of tumor cells. This heterogeneity has important implications for patient selection — immunohistochemical screening before enrollment in mesothelin-targeted trials helps identify patients most likely to benefit from CAR-T therapy.

While mesothelin's limited expression on normal tissues makes it a relatively safe target, on-target/off-tumor toxicity to healthy mesothelial surfaces remains a clinical concern. Two cases of severe pulmonary toxicity were reported with a highly active, fully human anti-mesothelin CAR administered intravenously, though earlier studies using regional (intrapleural) delivery showed no such toxicity — supporting the safety advantage of the regional approach.

Fibroblast Activation Protein (FAP)

FAP is a cell-surface serine protease predominantly expressed on cancer-associated fibroblasts within the tumor stroma rather than on tumor cells directly. Importantly, FAP expression has been confirmed across all mesothelioma histological subtypes, making it an appealing target that addresses the stromal compartment of the tumor microenvironment. A phase I trial (FAPME, NCT01722149) treated three mesothelioma patients with intrapleurally administered anti-FAP CAR-T cells, demonstrating safety with no treatment-related toxicities and detectable CAR-T cells in peripheral blood after treatment.

Recent imaging studies using FAP-targeted PET/CT (68Ga-FAPI-46) have demonstrated that FAP expression has significant prognostic value in mesothelioma and outperforms standard FDG PET/CT in tumor detection sensitivity and specificity — findings that could help identify optimal candidates for FAP-targeted CAR-T therapy.

Other Targets Under Investigation

Target	Relevance to Mesothelioma	Status
HER2 (ErbB2)	Expressed in some mesotheliomas; safety profile improving with low-affinity approaches	Preclinical/early phase
GD2	Dual-targeting with B7-H3 validated in preclinical models	Preclinical
B7-H3	Broadly expressed in solid tumors; nanoCAR-T approach tested preclinically	Preclinical
MET	Aberrant expression prevalent in mesothelioma; anti-tumor activity demonstrated	Preclinical
MUC16 (CA-125)	Primarily relevant for peritoneal mesothelioma and ovarian cancer	Early clinical (ovarian); preclinical (mesothelioma)

The diversity of potential targets reflects both the heterogeneity of mesothelioma biology and the growing sophistication of CAR-T engineering. Dual-targeting approaches that address two antigens simultaneously are being developed to overcome the challenge of antigen-negative tumor escape — a critical limitation of single-target CAR-T therapies.

What Have Clinical Trials Shown?

MSKCC Phase I Trial (NCT02414269) — The Landmark Study

The most important mesothelioma CAR-T trial to date, led by Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center, evaluated regionally delivered autologous mesothelin-targeted CAR-T cells in 27 patients (25 with malignant pleural mesothelioma). Patients received intrapleural infusions of 0.3 million to 60 million CAR-T cells per kilogram through an image-guided pleural catheter.

Key findings from this practice-changing trial include:

• Treatment was safe and well tolerated with only grade 1-2 adverse events and no evidence of immunogenicity or severe cytokine release syndrome
• CAR-T cells persisted in peripheral blood for more than 100 days in 39% (13 of 27) of patients, with persistence correlated to tumor regression
• Eighteen patients also received pembrolizumab (anti-PD-1) to rescue exhausted CAR-T cells
• In a subset of 11 mesothelioma patients receiving CAR-T plus pembrolizumab, the overall response rate was 72%, including 2 complete metabolic responses and 6 partial responses
• In 16 patients who received lymphodepleting chemotherapy: 12-month overall survival was 80.2%, and the best overall response rate was 63%
• PD-L1 expression level did not predict response — 6 of 8 responses occurred in PD-L1-low patients, suggesting the treatment works regardless of PD-L1 status

The 72% response rate is remarkable for a solid tumor CAR-T trial, where response rates typically range from 10-30%. This result validated both the mesothelin target and the intrapleural delivery approach as a viable strategy for mesothelioma treatment.

University of Pennsylvania huCART-meso (NCT03054298)

The Penn program evaluated fully humanized mesothelin-targeted CAR-T cells (huCART-meso) incorporating a 4-1BB/TCRζ signaling design in 20 patients across multiple tumor types (5 mesothelioma, 14 ovarian cancer, 1 lung adenocarcinoma). Patients received huCART-meso via intravenous, intrapleural, or intraperitoneal routes, with or without lymphodepletion.

Results showed cytokine release syndrome in 35% (7 of 20) of patients, with the best overall response being stable disease in 60% (12 of 20) and maximum tumor volume reduction of 41%. The median overall survival was 26.1 weeks and median progression-free survival was 12.3 weeks. Notably, huCART-meso cells demonstrated long-term persistence — detectable at Day 21 in 16 of 20 patients and persisting at 12 months in 5 patients, with one patient showing detectable cells for over two years.

MSKCC Next-Generation Trial (NCT04577326)

Building on the original trial's success, Adusumilli's team developed M28z1XXPD1DNR — a mesothelin-targeted CAR engineered with a PD-1 dominant-negative receptor (DNR) that acts as a decoy, preventing PD-1-mediated T cell exhaustion without requiring concurrent anti-PD-1 antibody therapy. This approach could eliminate the need for lifelong checkpoint inhibitor co-administration, reducing both costs and side effects.

NCI TNhYP218 Trial (NCT06885697)

A 2025-initiated National Cancer Institute trial is testing TNhYP218 CAR-T cells, which use a novel anti-mesothelin antibody (hYP218) that binds a membrane-proximal epitope of mesothelin — a fundamentally different binding site than most existing constructs. The trial employs T-naive/stem cell memory (Tnaive/SCM) cell populations designed for improved persistence.

Currently Recruiting CAR-T Trials (as of January 2026)

Trial ID	Target	Phase	Sponsor/Site
NCT05703854	CAR.70 + NK cells	Phase 1/2	MD Anderson Cancer Center
NCT06051695	Mesothelin (logic-gated)	Phase 1	Multiple sites (EVEREST-2)
NCT06256055	CAR-T	Phase 1	Academic center
NCT06885697	TNhYP218 (novel mesothelin)	Phase 1/2	National Cancer Institute
NCT06726564	Pleural delivery	Phase 1	Academic center
SynKIR-110	Mesothelin KIR-CAR	Phase 1	Penn, MD Anderson, Kansas, Wisconsin

As of January 2026, 93 mesothelioma clinical trials are actively recruiting worldwide, with 32 testing immunotherapy approaches and 5 specifically evaluating CAR-T cell therapy. No mesothelioma CAR-T program has yet advanced beyond phase I/II, but the encouraging results from the MSKCC trial have accelerated investment in larger studies. Patients interested in learning about clinical trial eligibility should discuss options with their oncology team and may also benefit from legal guidance regarding compensation for treatment-related expenses.

Why Is Intrapleural Delivery Important for Mesothelioma?

Regional delivery of CAR-T cells directly into the pleural cavity is a defining innovation of mesothelioma CAR-T research, pioneered at MSKCC by Dr. Adusumilli's team. The scientific rationale is compelling: mesothelioma is a surface-based malignancy that typically remains confined to the pleural cavity, making it uniquely accessible to locally delivered cellular therapy. By injecting CAR-T cells directly where the cancer resides, physicians achieve much higher concentrations of immune cells at the tumor site while minimizing exposure to the rest of the body.

Preclinical studies using animal models of mesothelioma demonstrated that intrapleurally administered CAR-T cells vastly outperformed systemically (intravenously) infused T cells. Both routes delivered equivalent numbers of T cells to the pleural tumor, but intrapleurally delivered cells achieved superior activation, more complete tumor eradication, and longer persistence. A critical finding was that intrapleurally delivered CAR-T cells also circulated systemically and could control tumors at distant sites, functioning through what researchers describe as a "regional distribution center" model — delivering local treatment with systemic reach.

In the clinical setting, intrapleural delivery at MSKCC was performed using image-guided interventional radiology techniques, with CAR-T cells administered through a pleural catheter. This approach proved remarkably safe: no severe cytokine release syndrome or off-tumor toxicity was observed, in contrast to intravenous mesothelin CAR-T approaches, which produced two cases of severe pulmonary toxicity in a separate trial. The safety differential between regional and systemic delivery has become one of the strongest arguments for the intrapleural approach in mesothelioma.

For patients with peritoneal mesothelioma, the same logic applies to intraperitoneal delivery, with the Penn huCART-meso trial including intraperitoneal administration as a delivery route. The minimally invasive surgical techniques used for pleural access in mesothelioma treatment are well established, providing a familiar procedural framework for regional CAR-T delivery.

What Are the Challenges of Using CAR-T in Solid Tumors?

While CAR-T therapy has achieved extraordinary results in blood cancers, translating this success to solid tumors like mesothelioma faces fundamental biological barriers that researchers are actively working to overcome.

Immunosuppressive tumor microenvironment (TME): The mesothelioma tumor microenvironment contains a complex array of immunosuppressive factors including TGF-β, IL-10, VEGF, and IL-4, along with regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) that actively suppress CAR-T cell function. This hostile environment can effectively "switch off" even highly activated CAR-T cells.

Physical barriers: Dense stromal matrix, poor T cell infiltration, and tumor hypoxia (low oxygen levels) limit CAR-T cell access to cancer cells. Unlike blood cancers where CAR-T cells freely circulate alongside their targets, in solid tumors the engineered cells must physically penetrate tissue barriers to reach cancer cells.

Antigen heterogeneity: Not all mesothelioma cells express the target antigen, creating a risk of antigen-negative tumor escape. As noted, mesothelin expression is diffuse in only 37% of epithelioid tumor specimens, meaning some cancer cells may evade even a highly effective mesothelin-targeted CAR-T therapy.

T cell exhaustion: CAR-T cells become functionally impaired in the hostile tumor microenvironment, losing proliferative capacity and cytotoxic function over time. This exhaustion is mediated in part by checkpoint molecules like PD-1 — which is why combining CAR-T with anti-PD-1 therapy (pembrolizumab) has proven so effective at MSKCC.

Trafficking: When administered intravenously, CAR-T cells must travel from the bloodstream to the tumor site, a significant barrier for solid tumors. This challenge is precisely why the intrapleural delivery approach has been so important for mesothelioma.

Researchers are developing multiple engineering strategies to overcome these barriers, including armored CARs that secrete pro-inflammatory cytokines, dominant-negative TGF-β receptor CARs (SMART CAR-T) that convert suppressive signals into activating ones, CRISPR-edited PD-1 knockout CARs, and the PD-1 dominant-negative receptor approach used in the MSKCC next-generation trial.

What Are the Safety Risks of CAR-T Therapy?

Cytokine Release Syndrome (CRS)

CRS is the most common serious adverse event associated with CAR-T therapy. When CAR-T cells activate and begin killing cancer cells, they release large amounts of inflammatory cytokines that can cause symptoms ranging from fever and fatigue (mild) to hypotension, organ dysfunction, and potentially life-threatening complications (severe). In blood cancer treatments, CRS incidence ranges from 56% in diffuse large B-cell lymphoma to 100% in pediatric ALL, though the mortality rate is less than 1%. CRS typically develops within the first week after infusion and resolves within 7-8 days with appropriate management including tocilizumab (anti-IL-6 receptor) and corticosteroids.

In mesothelioma trials, CRS has been notably milder. The MSKCC intrapleural trial reported only grade 1-2 adverse events with no severe CRS — a favorable profile likely attributable to regional delivery, which achieves high local concentrations without flooding the systemic circulation with activated T cells. The Penn huCART-meso trial observed CRS in 35% (7 of 20) of patients, consistent with the somewhat higher rates expected with intravenous delivery routes.

Neurotoxicity (ICANS)

Immune effector cell-associated neurotoxicity syndrome (ICANS) affects approximately 27-65% of patients receiving anti-CD19 CAR-T therapy for blood cancers, with symptoms including confusion, language difficulties, and in severe cases, seizures. In mesothelioma trials, ICANS has not been a significant clinical concern, likely because mesothelin — the primary target — is not expressed in the central nervous system.

On-Target/Off-Tumor Toxicity

Because mesothelin is expressed at low levels on normal mesothelial surfaces (pleura, peritoneum, pericardium), CAR-T cells may attack healthy tissue in addition to tumor cells. Two cases of severe pulmonary toxicity were observed with a highly potent, fully human anti-mesothelin CAR administered intravenously. This risk has driven the development of affinity-tuned CARs that use lower-affinity binding domains to preferentially target cells with high mesothelin expression (cancer cells) while sparing cells with low expression (normal tissue).

The HER2 Fatality — A Defining Safety Lesson

The most significant safety event in CAR-T history for solid tumors occurred in 2010 when a patient with colon cancer received HER2-directed CAR-T cells at the National Cancer Institute. The CAR-T cells recognized HER2 expressed on normal lung epithelium, triggering a massive cytokine storm, pulmonary toxicity, and fatal multi-organ failure. This tragic case profoundly influenced all subsequent CAR-T safety design, leading directly to the adoption of dose-escalation protocols, affinity tuning, suicide switches (genetic "off switches" that can eliminate CAR-T cells if toxicity occurs), and the regional delivery strategies that have proven so important in mesothelioma.

How Are CAR-T Cells Manufactured?

CAR-T manufacturing is a complex, multi-step process requiring specialized GMP (Good Manufacturing Practice) facilities and typically takes 3-5 weeks from blood collection to patient infusion.

Step 1 — Leukapheresis: T cells are collected from the patient's peripheral blood in a procedure lasting approximately 4 hours, completed as an outpatient procedure in a single day. A specialized machine separates white blood cells from the rest of the blood, collecting the T cells needed for engineering.

Step 2 — T cell activation and transduction: In the laboratory, collected T cells are activated and genetically modified to express the CAR using viral vectors. The MSKCC program uses retroviral transduction while the Penn program employs lentiviral vectors — both are safe, well-established methods for gene delivery.

Step 3 — Ex vivo expansion: The modified T cells are expanded over 1-2 weeks in bioreactors, growing from a small collection to the billions of cells needed for therapeutic doses.

Step 4 — Quality control and formulation: The final product undergoes rigorous testing for CAR expression levels, cell viability, sterility, and potency before being released for patient use.

Step 5 — Lymphodepletion conditioning: Before receiving the CAR-T infusion, patients typically receive lymphodepleting chemotherapy (cyclophosphamide with or without fludarabine) to create a favorable immunologic environment. In the MSKCC trial, lymphodepletion was associated with dramatically improved outcomes — 100% 6-month overall survival in patients receiving lymphodepletion.

Next-generation rapid manufacturing platforms are emerging that can produce CAR-T cells in as little as 24-48 hours by eliminating the ex vivo expansion phase, with T cells instead expanding in vivo after infusion. These approaches could dramatically improve patient access, reduce costs, and potentially produce T cells with improved fitness and clinical efficacy.

Allogeneic (off-the-shelf) CAR-T cells derived from healthy donors represent another approach to overcoming manufacturing barriers. CRISPR-Cas9 gene editing can knock out genes that cause graft-versus-host disease, enabling universal donor cells. While no allogeneic CAR-T product specific to mesothelioma has entered clinical trials, the platform is rapidly advancing in blood cancers.

Can CAR-T Therapy Be Combined with Other Treatments?

CAR-T Plus Checkpoint Inhibitors

The combination of CAR-T cells with anti-PD-1 therapy (such as pembrolizumab) is the most extensively studied and most successful approach in mesothelioma. When CAR-T cells enter the tumor microenvironment, they can become "exhausted" through PD-1/PD-L1 signaling — essentially being switched off by the tumor. Adding pembrolizumab blocks this exhaustion pathway, rescuing the CAR-T cells and restoring their cancer-killing function. This combination strategy produced the remarkable 72% response rate in the MSKCC trial, demonstrating that CAR-T and checkpoint inhibitors are synergistic — working together far better than either approach alone.

The next-generation MSKCC CAR (M28z1XXPD1DNR) incorporates a PD-1 dominant-negative receptor directly into the CAR construct, potentially achieving the same checkpoint-resistant effect without requiring concurrent antibody therapy — a design that could simplify treatment and reduce costs.

CAR-T Plus Chemotherapy

Lymphodepleting chemotherapy before CAR-T infusion is a standard component of most protocols. In the MSKCC trial, patients who received lymphodepletion achieved 100% 6-month overall survival compared to lower rates without, and the 12-month OS reached 80.2% in the lymphodepleted cohort. However, more aggressive lymphodepletion has been linked to both higher CAR-T expansion and increased CRS risk, requiring careful dose optimization.

CAR-T Plus Surgery

A logical combination for mesothelioma involves CAR-T therapy following surgical cytoreduction — such as pleurectomy/decortication or extrapleural pneumonectomy — to address residual microscopic disease. The intrapleural delivery model, where CAR-T cells are administered directly to the surgical cavity, provides a natural framework for this combined approach.

How Much Does CAR-T Therapy Cost?

CAR-T therapy is among the most expensive cancer treatments available. The six FDA-approved CAR-T products carry list prices ranging from $373,000 to $475,000 per infusion:

Product	Approved Indication	U.S. List Price
Kymriah (tisagenlecleucel)	ALL, DLBCL	$373,000-$475,000
Yescarta (axicabtagene ciloleucel)	DLBCL	$373,000
Tecartus (brexucabtagene autoleucel)	MCL	$373,000
Breyanzi (lisocabtagene maraleucel)	DLBCL	$410,300
Abecma (idecabtagene vicleucel)	Multiple myeloma	$419,500
Carvykti (ciltacabtagene autoleucel)	Multiple myeloma	$465,000

When hospitalization, monitoring, management of side effects, and supportive care are included, total treatment expenses can exceed $1 million per patient. In Europe, CAR-T list prices are approximately €320,000, with estimated pre- and post-treatment costs adding approximately €50,000 per patient.

CAR-T therapy for mesothelioma is currently available only through clinical trials, where treatment costs are typically covered by the trial sponsor. Trials are concentrated at major academic cancer centers including MSKCC, University of Pennsylvania, MD Anderson Cancer Center, and the NCI. If CAR-T therapy eventually receives FDA approval for mesothelioma, pricing is expected to be comparable to existing products, presenting significant reimbursement challenges.

Mesothelioma patients facing the financial burden of cancer treatment should be aware that multiple avenues of compensation may be available, including asbestos trust funds, personal injury lawsuits, and veterans' benefits for those with military asbestos exposure. These resources can help offset treatment costs for both standard and experimental therapies.

How Does CAR-T Compare to Other Immunotherapies for Mesothelioma?

Nivolumab Plus Ipilimumab — The Current Standard

On October 2, 2020, the FDA approved nivolumab plus ipilimumab (Opdivo + Yervoy) as first-line treatment for unresectable malignant pleural mesothelioma based on the phase III CheckMate 743 trial. This landmark randomized study of 605 patients demonstrated that dual checkpoint blockade significantly improved overall survival versus standard chemotherapy, with a median overall survival of 18.1 months and a hazard ratio of 0.74 (p = 0.002). With 5-year follow-up data, nivolumab plus ipilimumab continues to show durable survival benefit, establishing immunotherapy as the new standard of care.

How CAR-T Differs from Checkpoint Inhibitors

CAR-T therapy and checkpoint inhibitors operate through fundamentally different mechanisms. Checkpoint inhibitors "release the brakes" on pre-existing immune cells, allowing the body's own T cells to recognize and attack cancer. CAR-T provides an entirely new, engineered immune response — creating cancer-fighting cells that did not previously exist in the patient's body. The two approaches appear highly synergistic, as demonstrated by the MSKCC trial's combination strategy. CAR-T is currently being evaluated in later-line settings (after prior chemotherapy), but could potentially move to first-line if efficacy is confirmed in larger trials.

Other Cellular Therapies

Several other cellular immunotherapy approaches are under investigation for mesothelioma. Dendritic cell vaccines have advanced furthest in the Netherlands, with the phase III DENIM trial evaluating an allogeneic DC vaccine. CAR-macrophage therapy (CAR-M), developed by Carisma Therapeutics as CT-0508, represents another novel approach. In a phase I study, this HER2-directed CAR-macrophage therapy demonstrated a tolerable safety profile with no dose-limiting toxicities, no severe CRS or ICANS, and evidence of trafficking to and remodeling of the tumor microenvironment. The FDA granted CT-0508 fast track designation in September 2021.

What Future Developments Are Expected?

Bispecific and Logic-Gated CARs

Dual-targeting CARs that address two antigens simultaneously represent one of the most promising strategies to prevent antigen-negative tumor escape. The EVEREST-2 trial (NCT06051695) is evaluating a logic-gated mesothelin CAR-T that incorporates HLA-based safety mechanisms, allowing the CAR to distinguish between cancer cells and normal tissues with greater precision than conventional single-target designs.

CRISPR-Edited CAR-T

CRISPR-Cas9 gene editing enables precise modifications to CAR-T cells, including knockout of the PD-1 inhibitory receptor to prevent exhaustion, deletion of the T cell receptor to enable allogeneic (donor-derived) use, and removal of adenosine A2A receptors to resist immunosuppression in the tumor microenvironment. MPTK-CAR-T cells — with both PD-1 and TCR disrupted — have already been evaluated in a phase I dose-escalation study targeting mesothelin with a manageable safety profile.

CAR-NK Cells

Natural killer (NK) cells engineered with chimeric antigen receptors offer several potential advantages over CAR-T cells: reduced risk of graft-versus-host disease and CRS, enabling off-the-shelf manufacturing from healthy donors without HLA matching. Recent research suggests that CD28 co-stimulation is superior to 4-1BB for CAR-NK cell function — an interesting contrast to the ongoing debate about co-stimulatory domains in CAR-T cells.

Rapid and Decentralized Manufacturing

Next-generation manufacturing platforms that compress the production timeline from weeks to 24-48 hours could transform CAR-T accessibility. By eliminating ex vivo expansion and enabling in vivo expansion after infusion, these platforms also produce T cells with improved replicative potential. Decentralized, point-of-care manufacturing could bring CAR-T therapy to community hospitals rather than requiring treatment at a handful of major academic centers.

What Do Current Treatment Guidelines Say About CAR-T for Mesothelioma?

As of 2025, CAR-T cell therapy is not yet included in formal treatment guidelines for mesothelioma. The 2025 ASCO Guideline Update for Treatment of Pleural Mesothelioma includes evidence-based recommendations for surgical cytoreduction, immunotherapy (nivolumab plus ipilimumab as first-line), chemotherapy, pathology, and germline testing — but does not address CAR-T, as no product has progressed beyond phase I/II trials for this indication.

Similarly, the NCCN Clinical Practice Guidelines for malignant pleural mesothelioma recommend checkpoint immunotherapy and chemotherapy as standard systemic treatments but do not include CAR-T among recommended options. This reflects the early clinical stage of CAR-T development for mesothelioma rather than a judgment about its potential — the encouraging phase I results have generated significant enthusiasm in the research community.

Expert consensus suggests that FDA approval of a mesothelioma-specific CAR-T product is likely 5-10 years away, contingent on successful completion of larger randomized trials that confirm the phase I results. In the meantime, patients with mesothelioma can access CAR-T therapy through clinical trials at specialized centers. Understanding the available clinical trial landscape is an important part of treatment planning, and patients may benefit from consulting with mesothelioma specialists and legal professionals who can help navigate both medical options and compensation resources to support treatment.

Frequently Asked Questions

What is CAR-T cell therapy and how does it work against mesothelioma?

CAR-T (chimeric antigen receptor T-cell) therapy is a form of immunotherapy in which a patient's own T cells are collected, genetically engineered in a laboratory to express a synthetic receptor that recognizes a specific protein on cancer cells, and then infused back into the patient. For mesothelioma, the primary target is mesothelin, a protein overexpressed on the surface of mesothelioma cells. Once engineered, these CAR-T cells can identify and destroy mesothelin-positive cancer cells through multiple killing mechanisms, acting as a "living drug" that can persist in the body for months.

Is CAR-T therapy FDA-approved for mesothelioma?

No. As of 2026, no CAR-T product is FDA-approved for mesothelioma or any other solid tumor. Six CAR-T products are approved for blood cancers (leukemia, lymphoma, and multiple myeloma). CAR-T therapy for mesothelioma is available only through clinical trials at specialized academic cancer centers. Expert estimates suggest FDA approval for a mesothelioma-specific product could be 5-10 years away.

What were the results of the MSKCC CAR-T trial for mesothelioma?

The MSKCC phase I trial (NCT02414269) achieved groundbreaking results: a 72% overall response rate in patients receiving intrapleural mesothelin-targeted CAR-T cells combined with pembrolizumab, including 2 complete metabolic responses. Among patients receiving lymphodepleting chemotherapy, 12-month overall survival reached 80.2%. These are the best CAR-T results ever reported in a solid tumor.

Why is CAR-T delivered directly into the chest for mesothelioma?

Intrapleural (regional) delivery achieves several advantages over intravenous administration: higher concentrations of CAR-T cells at the tumor site, reduced systemic toxicity, superior T cell activation, and longer persistence. Preclinical studies showed intrapleural delivery vastly outperformed intravenous delivery, and clinical data confirmed a much safer profile with no severe CRS compared to IV approaches. Importantly, intrapleurally delivered cells also circulate systemically and can control distant tumors.

What are the side effects of CAR-T therapy?

The most common serious side effect is cytokine release syndrome (CRS), which causes fever, low blood pressure, and potentially organ dysfunction. In blood cancer treatments, CRS occurs in 56-100% of patients but has less than 1% mortality with appropriate management. In mesothelioma trials using intrapleural delivery, CRS has been notably milder, with the MSKCC trial reporting only grade 1-2 events. Other potential risks include neurotoxicity (rare in mesothelioma) and on-target/off-tumor effects on normal mesothelial tissue.

How much does CAR-T therapy cost?

FDA-approved CAR-T therapies carry list prices of $373,000 to $475,000 per infusion, with total treatment costs potentially exceeding $1 million when hospitalization and supportive care are included. CAR-T for mesothelioma is currently available only through clinical trials, where costs are typically covered by the trial sponsor. If eventually approved for mesothelioma, compensation through asbestos trust funds and legal claims may help offset treatment costs.

Who is eligible for CAR-T clinical trials for mesothelioma?

Eligibility varies by trial but generally requires a confirmed diagnosis of malignant mesothelioma (typically pleural subtype), adequate organ function, and prior treatment with standard therapies. For mesothelin-targeted trials, tumors must express mesothelin, which is confirmed through immunohistochemical testing. Trials are currently available at MSKCC, MD Anderson, University of Pennsylvania, NCI, and other academic centers. Patients should discuss trial eligibility with their oncology team.

How long does the CAR-T manufacturing process take?

The standard manufacturing process takes 3-5 weeks from blood collection (leukapheresis) to patient infusion. During this waiting period, patients may receive bridging therapy to control their disease. Next-generation rapid manufacturing platforms under development could reduce this timeline to 24-48 hours, and allogeneic (off-the-shelf) CAR-T products could eliminate the manufacturing wait entirely by using pre-made cells from healthy donors.

Related Pages

• Understanding Your Diagnosis
• Pleural Mesothelioma
• TTFields / Optune Lua for Mesothelioma
• VATS and Thoracoscopic Procedures
• Pleurectomy/Decortication
• Extrapleural Pneumonectomy
• Asbestos Trust Fund Quick Reference
• Veterans Mesothelioma Quick Reference
• Occupational Asbestos Exposure Quick Reference

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.